Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Organic Chemistry >  Phosphines >  Zoledronic acid

Zoledronic acid

Basic information Safety Supplier Related

Zoledronic acid Basic information

Product Name:
Zoledronic acid
Synonyms:
  • 2-(imidazole-1-yl)-1-acetic acid HCl
  • CGP-42446
  • Zoledronic Acid API
  • sMall aMount
  • Aclasta
  • BPH 91
  • Orazol
  • Reclast
CAS:
118072-93-8
MF:
C5H10N2O7P2
MW:
272.09
EINECS:
1806241-263-5
Product Categories:
  • TGF-beta/Smad
  • APIs
  • All Inhibitors
  • Inhibitors
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • Pharmaceutical material and intermeidates
  • Bone resorption inhibitor
  • Antiosteoporotic
  • Zoledronate
  • Zoledronic
  • Smad
  • TGF-beta
Mol File:
118072-93-8.mol
More
Less

Zoledronic acid Chemical Properties

Melting point:
193-2040C (dec)
Boiling point:
764.0±70.0 °C(Predicted)
Density 
2.13±0.1 g/cm3(Predicted)
pka
1.41±0.10(Predicted)
CAS DataBase Reference
118072-93-8(CAS DataBase Reference)
More
Less

Safety Information

Hazard Codes 
Xi
Risk Statements 
21/22-36/37/38
Safety Statements 
24/25-36/37/39
HS Code 
2933399090
More
Less

Zoledronic acid Usage And Synthesis

Description

Zoledronic acid is a white, crystalline powder that is available in vials for reconstitution for IV infusion over at least 15 minutes. It does not undergo metabolic transformation and does not inhibit CYP450 enzymes. Clearance of this agent is dependent on the patient's creatinine clearance, not on dose. Serum creatinine levels should be evaluated before every treatment. Zolendronic acid is contraindicated in patients with severe renal impairment.

Chemical Properties

White Solid

Originator

Zometa,Novartis Pharma,Switz

Uses

Bisphosphonate antiresorptive agent

Uses

bone resorption inhibitor

Definition

ChEBI: An imidazole compound having a 2,2-bis(phosphono)-2-hydroxyethane-1-yl substituent at the 1-position.

Manufacturing Process

With stirring and under reflux, 8.6 g (0.053 mole) of imidazol-4-yl acetic acid hydrochloride, 7.1 ml of 85% phosphoric acid and 25 ml of chlorobenzene are heated to 100°C. Then 13.9 ml of phosphorus trichloride are added dropwise at 100°C, whereupon evolution of gas occurs. Over the course of 30 min a dense mass precipitates from the reaction mixture. The batch is heated for 3 hours to 100°C and the supernatant chlorobenzene is removed by decantation. With stirring and under reflux, the residual viscous mass is heated to the boil for 3 hours with 40 ml of 9 N hydrochloric acid. The batch is filtered hot with the addition of carbon and the filtrate is diluted with acetone, whereupon the crude 2-(imidazol-4-yl)-1-hydroxy-ethane-1,1- diphosphonic acid precipitates. This product is recrystallised from water. Melting point: 238-240°C (dec.).

brand name

Zometa (Novartis).

Therapeutic Function

Bone calcium regulator

Biological Functions

Zoledronic acid, a bisphosphonate, was approved by the U.S. FDA in 2001 for the treatment of hypercalcemia of malignancy, a metabolic complication that can be life-threatening. Hypercalcemia of malignancy can occur in up to 50% of patients diagnosed with advanced breast cancer, multiple myeloma, and nonsmall cell lung cancer. This condition arises when chemical moieties produced by the tumor cause overstimulation of osteoclasts. When there is an increase in bone degradation, there is a concomitant release of calcium into the plasma. When serum concentrations of calcium rapidly elevate, the kidneys are unable to handle the overload, and hypercalcemia results. This can lead to dehydration, nausea, vomiting, fatigue, and confusion. Zoledronic acid effectively decreases plasma calcium concentrations via inhibition of bone resorption (inhibition of osteoclastic activity and induction of osteoclast apoptosis). It also prevents the increase in osteoclastic activity caused by tumor-based stimulatory factors. Additionally zoledronic acid has been approved by the U.S. FDA for the treatment of multiple myeloma and bone metastases associated with solid tumor–based cancers (e.g., prostrate and lung). This agent is currently in late-stage clinical trials for the treatment and prevention of osteoporosis and, if approved, will be formulated as a 5-mg, once-yearly IV infusion.

Clinical Use

Zoledronic acid is most commonly given to patients whose cancer is no longer responding to hormones, but it also may be given to prevent the bone thinning and weakening that results from hormonal treatments.

Zoledronic acidSupplier

INTATRADE GmbH
Tel
+49 3493/605464
Email
sales@intatrade.de
Chembest Research Laboratories Limited
Tel
021-20908456-
Email
sales@BioChemBest.com
TAIYUAN RHF CO.,LTD.
Tel
+86 351 7031519
Email
sales@RHFChem.com
BeiJing Hwrk Chemicals Limted
Tel
0757-86311057-
Email
kennyrong@hwrkchemical.com
Capot Chemical Co., Ltd
Tel
+86 (0) 571 85 58 67 18
Email
sales@capotchem.com